Dr. Robert Wesolowski, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 142
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OH license 35.095721
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 142
- Services billed
- 330
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 160 | 106 |
| Established patient office or other outpatient visit, 40-54 minutes | 85 | 37 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ibrance (palbociclib) | 72 |
| Anastrozole Other prescribers in Columbus, OH | 57 |
| Prochlorperazine Maleate Other prescribers in Columbus, OH | 19 |
| Kisqali (ribociclib succinate) | 19 |
| Letrozole Other prescribers in Columbus, OH | 18 |
| Tamoxifen Citrate Other prescribers in Columbus, OH | 18 |
| Alendronate Sodium Other prescribers in Columbus, OH | 16 |
| Exemestane | 16 |
| Gabapentin Other prescribers in Columbus, OH | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $1,890 in total to this clinician.
| Pfizer Inc. | $1,890 |
|---|
| Consulting Fee | $1,890 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jan 22, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $1,890 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $375,901 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Eli Lilly and Company - BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Beone Medicines USA, Inc. · Recruiting · NCT06120283 - First-in-human study of STX-478, a mutant-selective PI3KA inhibitor as monotherapy and in combination with other antineoplastic agents in participants with advanced solid tumors
Eli Lilly and Company - ALI-1201
Puma Biotechnology, Inc. - The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.